CPT code 32560 captures bedside chemical pleurodesis performed by instilling a sclerosing agent such as talc into the pleural space through a chest tube or catheter. This code is clinically important for management of recurrent pleural effusions and malignant pleural disease where pleurodesis is indicated to prevent reaccumulation of fluid. Nationally, the code matters for hospital inpatient and procedural billing, clinical documentation of pleurodesis, and for comparisons of procedural utilization related to pleural disease.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical service represented by the code, payer coverage context, and what types of benchmarks and policy considerations typically accompany analysis of this procedure. The publication outlines where the service is commonly performed, documentation elements that support use of the code, and the kinds of benchmarking and policy updates that affect reimbursement and utilization tracking.

The report is intended to inform coding professionals, hospital revenue leaders, and clinical stakeholders about the role of CPT code 32560 in pleural disease management, payer coverage landscapes, and the operational settings where the procedure is delivered. Data not available in the input is noted where applicable.